Atypical antipsychotic tolerability and switching strategies in bipolar disorder

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 17, 2010, Pages 2827-2837

  Liauw, Samantha S ^a,b   McIntyre, Roger S ^b,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atypical antipsychotics; Bipolar disorder; Obesity; Somnolence; Tardive dyskinesia; Tolerability; Weight gain

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; ILOPERIDONE; LITHIUM; MODAFINIL; OLANZAPINE; PALIPERIDONE; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMINAL OBESITY; BIPOLAR DISORDER; BODY MASS; CARDIOMYOPATHY; CLINICAL TRIAL; COGNITIVE DEFECT; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE SUSCEPTIBILITY; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; HUMANS;

EID: 78149440766     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.510835     Document Type: Review

References (62)

1. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
2. Leo RJ, Regno PD. Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. Prim Care Companion. J Clin Psychiatry 2000;2(6):194-204
3. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11(3):225-55
4. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28(9):2289-304
5. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: An international perspective. J Affect Disord 2010. [Epub ahead of print]
6. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46(3):273-81
7. Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. J Clin Psychiatry 2002;63(Suppl 4):24-32
8. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160(1):112-7
9. McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009;70(Suppl 3):5-11
10. Enns MW, Swenson JR, McIntyre RS, et al. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 2001;46(Suppl 1):77S-90S
11. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003;100(24):14293-6
12. Casey J, Johnson V, McClelland P. The relationship between interdialytic weight gain and patient compliance. A single centred cohort study (n = 21). EDTNA ERCA J 2001;27(4):187-9
13. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66(1):51-7
14. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;7:433-43
15. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
16. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs 2000;9(12):2935-43
17. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 2003;5(Suppl 2):62-79
18. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):28-36
19. McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010. [Epub ahead of print]
20. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68(10):1480-91
21. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61(1):9-15
22. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
23. Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66(8):838-47
24. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64(12):1426-35
25. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519-26
26. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(3):553-60
27. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22(7):433-43
28. Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009;70(4):487-99
29. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008;103(1-3):104-9
30. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160(4):741-8
31. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-9
32. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002;63(Suppl 3):15-20
33. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
34. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-17
35. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004;65(Suppl 6):20-9
36. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166(4):476-88
37. DeQuardo JR. Modafinil and antipsychotic-induced sedation. J Clin Psychiatry 2004;65(2):278-9
38. Makela EH, Miller K, Cutlip WD. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 2003;64(4):485-6
39. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006;67(1):107-13
40. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009;63(8):1237-48
41. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71(4):463-74
42. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2010. [Epub ahead of print]
43. Chung SJ, Jeong SH, Ahn YM, et al. A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(1):139-44
44. Calabrese JR, Woyshville MJ. A medication algorithm for treatment of bipolar rapid cycling? J Clin Psychiatry 1995;56(Suppl 3):11-8
45. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156(8):1164-9
46. Amann BL, Pogarell O, Mergl R, et al. EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol 2003;18(8):641-6
47. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65(4):464-70
48. Friman G, Wesslen L, Fohlman J, et al. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J 1995;16(Suppl O):36-41
49. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322(7296):1207-9
50. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24(1):62-9
51. Clevenger CV. Role of prolactin/ prolactin receptor signaling in human breast cancer. Breast Dis 2003;18:75-86
52. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;65(2):187-90
53. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61
54. Mihara K, Suzuki A, Kondo T, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001;105(3):271-4
55. Hanssens L, LItalien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95
56. Cutler AJ. Iloperidone: a new option for the treatment of schizophrenia. Expert Rev Neurother 2009;9(12):1727-41
57. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009;70(10):1340-7
58. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176(5):627-32
59. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009;70(10):1340-7
60. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):4-17
61. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009;29(2):165-9
62. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23(6):595-600